Medrol revenue trends
In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis. In 1Q17, Medrol generated revenues of ~$120 million, which represents a ~6% YoY rise and a 1% QoQ (quarter-over-quarter) rise.
Medrol (methylprednisolone) is an Adrenocortical steroid indicated for the treatment of various endocrine disorders, rheumatic disorders, dermatologic diseases, allergic states, ophthalmic diseases, ulcerative colitis, multiple sclerosis, hematologic disorders, collagen diseases, and respiratory disorders. The drug is also used for the palliative management of leukemias and lymphomas in adult patients.
Sulperazon revenue trends
In 2016, Pfizer’s Sulperazon reported revenues of ~$396 million in 2016, which reflected a ~17% YoY rise. In 1Q17, Sulperazon generated revenues of ~$122 million, which represented a ~27% YoY rise and a 31% QoQ rise.
Sulperazon is an antibiotic indicated for the treatment of various bacterial infections. Sulperazon is used as a monotherapy for the treatment of respiratory tract infections, urinary tract infections, peritonitis cholangitis, cholecystitis, and other soft tissue infections.
Tygacil revenue trends
In 2016, Tygacil reported revenues of ~$274 million, which reflected a ~10% YoY fall. In 1Q17, Tygacil generated revenues of ~$74 million, which represented a ~3% YoY fall and a 4% QoQ rise. Tygacil (tigecycline) is an antibacterial product indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.
Fragmin revenue trends
In 2016, Pfizer’s Fragmin reported revenues of ~$318 million, or ~5% lower YoY. In 1Q17, Fragmin generated revenues of ~$71 million, or ~9% lower YoY and 10% lower QoQ. The drug is an LMWH (low molecular weight heparin) indicated for prophylaxis of ischemic complications of unstable angina, non-Q wave myocardial infarction, deep-vein thrombosis during abdominal surgery, and hip replacement surgery. Fragmin is also used in the treatment of symptomatic venous thromboembolism to diminish relapse in patients with cancer.
The Vanguard Health Care ETF (VHT) has about ~5.5% of VHT’s total portfolio holdings in Pfizer. Pfizer’s peers in sterile injection pharmaceuticals market include Teva Pharmaceuticals (TEVA), GlaxoSmithKline (GSK), Sanofi (SNY), and AstraZeneca.